Renal cell carcinomas is 2-3% of all adult cancers. Kidney cancer is currently the seventh most common cancer in men and the tenth most common in women (1). There were 19,3 million new cancer diagnoses and 10 million cancer deaths worldwide in 2020 (2). Survival in renal cell carcinomas has a strong correlation with the stage of diagnosis. 5-year survival in stage 1 tumors is 93%, 72,5% in cases with local lymph node metastases and 12% in metastatic carcinomas cases (3). There is an inverse correlation between age / tumor size and survival. Metastatic lymph node, tumor necrosis and adipose tissue invasion are associated with poor prognosis (4). The study is including 179 renal cell carcinoma cases. The clinical and pathological datas of these cases were retrospectively analyzed from the Cumhuriyet University Hospital patient system. The distribution sex of cases are 111 males (62%) and 68 females (38%). The mean age of the 179 cases was 58,5±11,9 years (range of 21-90). The mean tumor diameter is 5,7±3,4 (range of 1-19 cm). The nuclear grades of cases are 53,1% with low grade and 46,8% with high grade. Radical nephrectomies were evaluated for vascular invasion, ureter invasion, capsule/adipose tissue invasion, lymph node metastasis and adrenal gland metastasis. There is a statistically significant relationship between nuclear grade and vein invasion, microvascular invasion, capsule/adipose tissue invasion (p
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.